HOME >> MEDICINE >> NEWS
Results of exercise test may predict death in patients with coronary artery disease

Exercise capacity, as measured in terms of VO2max, is a powerful predictor of death in patients with coronary artery disease, not just patients with heart failure. That is the finding of Mayo Clinic research presented today at the American Heart Association's Scientific Sessions 2005 in Dallas.

VO2max is the maximum amount of oxygen a person can take in during exercise. In a VO2max study, a patient walks on a treadmill for about 5 to 15 minutes and breathes through a valve; the oxygen and carbon dioxide in the expired air are measured. Results are given in milliliters of oxygen per kilogram of body weight per minute (ml/kg/min).

"The best predictor of survival in cardiac patients is their capacity for exercise," says Thomas Allison, Ph.D., the lead author of the study, who is from Mayo Clinic in Rochester, Minn. "When we considered all of the measurable clinical variables -- such as whether they had bypass surgery or whether they have diabetes or high blood pressure -- the patient's capacity for exercise as measured by VO2max stood clear as the best predictor for 10-year survival."

In this study, the significance of low VO2max levels was examined in patients with coronary artery disease -- the top cause of death in the United States and often a precursor to a heart attack and heart failure.

A group of 282 patients, 17 percent of them women, underwent cardiopulmonary treadmill testing at the end of cardiac rehabilitation and were followed for an average of 9.8 years. The average age was 61 at the time of the test.

In the first two years there were few deaths, but after that mortality was significantly higher in patients with low VO2max. Fifty-five patients had a low VO2max (less than 18 ml/kg/min); at 10 years, almost half (42 percent) had died. Of the 227 patients who had a VO2max above or equal to 18 ml/kg/min, only 11.6 percent had died at the 10-year mark. Even after adjusting for age, sex and ventricular function, VO2ma
'"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005, 507-284-251
Mayo Clinic
14-Nov-2005


Page: 1 2

Related medicine news :

1. Results of largest ever genome scan for autism out
2. Timely treatment of heart attacks: Results from the AMI-QUEBEC Study
3. Results of hospital performance measures do not always reflect patient outcomes
4. Results good for HER-2 positive breast cancer patients using trastuzumab
5. Results of clipping and coiling of aneurysms are similar over time
6. Results with newer bladeless LASIK equivalent to standard microkeratome LASIK
7. Traditional Chinese exercises may increase efficacy of flu vaccine
8. Even low levels of weekly exercise drive down blood pressure
9. Some women benefit more from exercise when emphasis is on health, not appearance
10. Strengthening exercises may slow progression of ALS
11. Research shows aerobic exercise helps maintain muscle in elderly

Post Your Comments:
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... for Women’s Cancer announce today that Dr. Beth ... of the Claudia Cohen Research Foundation Prize for Outstanding ... the Society of Gynecologic Oncology 46th Annual Meeting on ... of the Cedars-Sinai Women’s Cancer Program at the Samuel ...
(Date:3/29/2015)... 29, 2015 Youth Villages will participate ... Oregon to assess the feasibility of implementing a Pay ... behavioral problems and their families. , Third Sector Capital ... that will be provided technical assistance throughout 2015 toward ... six other national awardees chosen by Third Sector. The ...
(Date:3/28/2015)... Rocket Pure , a manufacturer of natural body ... new natural sunscreen. They are offering the sunscreen in ... come with a bonus lip balm sunscreen. , The new ... Click to see the natural sunscreen on Amazon . ... made with non-nano zinc oxide and provides broad-based protection against ...
(Date:3/28/2015)... Take a bite of warm, gooey ... Acids tumble into the stomach, ready to break down ... lets these acids run amok, triggering a burning sensation ... More than 60 million Americans have heartburn at least ... starts, and how it can be stopped. , Heartburn ...
(Date:3/28/2015)... New York, NY (PRWEB) March 28, 2015 ... clinic that offers urgent care in Manhattan, recently commemorated ... urgent care facility in Manhattan. In addition to 24-hour ... to ER facilities. , At this time, Emergency ... treatments for abdominal pain, asthma, chest pain, eye injuries, ...
Breaking Medicine News(10 mins):Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2
(Date:3/29/2015)...  Three-month paliperidone palmitate, an investigational atypical antipsychotic, ... in patients with schizophrenia, according to a new ... the Journal of the American Medical ... of the study served as the basis for ... three-month paliperidone palmitate injection to treat schizophrenia in ...
(Date:3/27/2015)... YORK , March 27, 2015 BioCorRx, ... Santa Ana, California is a healthcare ... for which is estimated at $22 billion in the U.S. ... the use of FDA-approved Naltrexone in a specially compounded form ... Australia and New Zealand ...
(Date:3/27/2015)... , March 27, 2015 Across the ... to meeting challenges in clinical development, market education, and ... regulations, the Medical Affairs function is expected to increase ... markets. According to research by benchmarking ... have a group dedicated to Medical Affairs. Among companies ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
Cached News: